Prostate cancer (PCa) is a common malignant tumour, which ranks the second most frequent cancer (1.4 million new cases) and the fifth leading cause of cancer-related deaths (375,000 deaths) among men in 2020 (Sung et al., 2021). Although great progress has been achieved in therapeutic over the past few decades, the 5-year overall survival of PCa patients is still poor because of the metastasis and recurrence (Wu et al., 2017). Most PCa patients are diagnosed at late stages due to these patients with symptoms hidden, which is an also contributor to the poor prognosis (Teo et al., 2019). Hence, identifying new biomarkers and molecular targets is essential to improve the treatment of PCa.As a new kind of non-coding RNAs (ncRNAs), circular RNAs (circRNAs) have become the latest focus of RNA research (Chen & Huang, 2018). CircRNAs are generated by pre-mRNA back splicing of precursor mRNA and are able to form covalent closed structures, which are characterized by tissue-specific, conservative evolution and stable structure (Liu et al., 2017). CircRNAs are abnormally expressed in many malignant tumours and have critical roles in

Micrornas (mirnas) are well established key players in tumorigenesis. Their emergence as potential diagnostic and prognostic biomarkers for cancer has demonstrated the importance of mirnas in cancer biology. although mir-486 is implicated in many types of cancer, its role in renal cell carcinoma (rcc) remains undetermined. in the present study, real-time quantitative Pcr (qPcr), wound scratch assay, cell proliferation assay, Transwell migration assay and flow cytometry were utilized to detect the miR-486 transcript and its role in proliferation, migration and apoptosis in rcc. The relationship between mir-486 expression and clinicopathological variables or overall survival was analyzed using 96 formalin-fixed paraffin-embedded (FFPE) RCC samples. The results of the present study revealed significant upregulation of mir-486 in rcc tissues and cell lines. Moreover, ectopic expression of mir-486 promoted cell proliferation, mobility and inhibited apoptosis in 786-o and acHn cell lines. In addition, the Cox proportional hazard regression analysis revealed that patients with low expression of mir-486 exhibited a markedly longer overall survival in the univariate and multivariate analyses. In conclusion, our findings indicate that mir-486 may serve as a novel prognostic biomarker but may also be applied as a new therapeutic approach for the treatment of rcc.